Tissue-specific MR imaging in multiple sclerosis

American Journal of Neuroradiology

Volumn 30, Issue 7, 2009, Pages 1277-1278

  Rovira, A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GADOLINIUM; GLATIRAMER; IMMUNOMODULATING AGENT; NATALIZUMAB;

BRAIN TISSUE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; EDITORIAL; GRAY MATTER; HISTOPATHOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; WHITE MATTER;

BRAIN; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED;

EID: 68549122543     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1777     Document Type: Editorial

References (18)

1. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapse in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:270-77
2. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006;59:597-05
3. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-45
4. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60: 1073-81
5. Arnold DL. Evidence for neuroprotection and remyelination using imaging techniques. Neurology 2007;68(suppl 3):S83-S90
6. Van Walderveen MA, Barkhoff F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45: 1684-90
7. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126(Pt 8): 1782-89
8. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007;68(suppl 3):S72-S82
9. Filippi M, Rovaris M, Rocca MA, et al, and the European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-33
10. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407-13
11. Bagnato F, Gupta S, Richert ND, et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005;62:1684-88
12. Van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlates of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-88
13. Li BS, Moriarty DM, Regal J, et al. In vivo 3D 1H MRS of T1-hypointense lesions in relapsing-remitting multiple sclerosis. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Glasgow, Scotland, UK, April 21-27, 2001
14. Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739-52
15. Fritz D, Dwyer MG, Quadros C, et al. T1 intensity differences to normal appearing white matter in hypointense lesions on MRI are related to clinical status in multiple sclerosis. J Neurol 2006;253:104-26
16. Riva M, Ikonomidou VN, Ostuni JJ, et al. Tissue-specific imaging as a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage. AJNR Am J Neuroradiol 2009;30:1394-401
17. Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1:284-94
18. Rice C, Scolding N. Strategies for achieving and monitoring myelin repair. J Neurol 2007;254:275-83